Overview

A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

Status:
Completed

Trial end date:
2018-05-16

Target enrollment:

Participant gender:

Summary

Dose escalation study to assess PK, safety and tolerability of INC280 when taken with food in patients with cMET dysregulated advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals